Therapeutic Area | MeSH |
---|---|
physiological phenomena | D010829 |
Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Skytrofa | lonapegsomatropin-tcgd | Ascendis Pharma | N-761177 RX | 2021-08-25 | 9 products |
Brand Name | Status | Last Update |
---|---|---|
skytrofa | Biologic Licensing Application | 2024-05-07 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Laron syndrome | D046150 | Orphanet_633 | E34.321 | — | — | 3 | — | 2 | 5 |
Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | — | 3 | — | — | 3 |
Pituitary dwarfism | D004393 | EFO_1001109 | E23.0 | — | — | 3 | — | — | 3 |
Pituitary diseases | D010900 | — | E23.7 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
Turner syndrome | D014424 | Orphanet_881 | Q96 | — | 1 | — | — | — | 1 |
Gonadal dysgenesis | D006059 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Drug common name | Lonapegsomatropin |
INN | lonapegsomatropin |
Description | Lonapegsomatropin, sold under the brand name Skytrofa, is a human growth hormone used for the treatment of growth hormone deficiency. Lonapegsomatropin is a prodrug of somatropin.
|
Classification | Protein |
Drug class | tricyclic compounds; atropine derivatives; PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL4298185 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB16220 |
UNII ID | OP35X9610Y (ChemIDplus, GSRS) |